[Lapatinib (Tyverb) for the treatment of metastatic breast cancer]
Comite d'Avaluacio de Medicaments d'Utilitzacio Hospitalaria (CAMUH)
Record ID 32010000706
Catalan
Authors' objectives:
To assess the efficacy, safety and efficiency of lapatinib in each of the indications approved by the EMA.
Authors' recommendations:
The combination of lapatinib with capecitabine and letrozole was more efficacious than capecitabine and letrozole in each of the studied indications in terms of time until progression and PFS, depending on the indication. Lapatinib is generally well-tolerated. However, diarrhea and skin rash are common. More studies are needed to define the hepatic and cardiac effects of lapatinib.
Details
Project Status:
Completed
Year Published:
2011
URL for published report:
http://www.gencat.cat/salut/depsan/units/aatrm/pdf/lapatinib_cancermama_metast_aiaqs2011ca.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Spain
MeSH Terms
- Protein Kinase Inhibitors
- Receptor, ErbB-2
Contact
Organisation Name:
Agencia de Qualitat i Avaluacio Sanitries de Catalunya
Contact Address:
Antoni Parada, CAHTA, Roc Boronat, 81-95 (2nd floor), 08005 Barcelona, Spain, Tel. +34 935 513 928, Fax: +34 935 517 510
Contact Name:
direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Contact Email:
direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Copyright:
Catalan Agency for Health Information, Assessment and Quality (CAHIAQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.